China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that a clinical trial filing for its 6MW3511 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for the company’s innovative oncology pipeline.
Drug Mechanism and Innovation
6MW3511 is a bifunctional protein linking an anti-PD-L1 nano antibody and a TGF-β RII mutant, designed to treat multiple advanced solid tumors. The drug simultaneously blocks the PD-1/PD-L1 and TGF-β pathways, addressing tumor microenvironment immunosuppression. Its simple structure enhances tumor penetration, potentially improving therapeutic efficacy.
Preclinical Results
Preclinical studies demonstrated that 6MW3511 exhibited good antitumor effects in vivo, with favorable animal tolerance. These results support the drug’s potential to become a valuable addition to the immunotherapy landscape for advanced solid tumors.-Fineline Info & Tech
